纳米病毒药物NV-387将麻疹感染小鼠的存活率延长了130%,可能为无法接种疫苗者提供治疗。 NanoViricides' drug NV-387 extended survival in measles-infected mice by 130% and may offer treatment for those unable to get vaccinated.

纳米病毒杀虫公司报告了对其实验性麻疹药物NV-387的前临床结果,显示它在感染小鼠中显著延长了130%的存活时间,并减少了肺损伤和炎症. NanoViricides reports promising preclinical results for its experimental drug NV-387 against measles, showing it significantly extended survival in infected mice by 130% and reduced lung damage and inflammation. 该药物在阻塞感染和保护组织方面模仿了一种病毒附着分子,现已完成了人类安全试验第一阶段,可用作口腔口香糖。 The drug, which mimics a viral attachment molecule to block infection and protect tissues, has completed a safe Phase I human trial and is available as oral gummies. 随着麻疹病例的增加和对疫苗有效性的担忧,NV-387可提供一种治疗选择,特别是对那些无法获得疫苗的人而言,尽管进一步发展取决于赠款和合同。 With rising measles cases and concerns over vaccine effectiveness, NV-387 could offer a treatment option, especially for those unable to receive vaccines, though further development depends on grants and contracts.